Galectin Therapeutics Inc. (GALT)

[thefamilyman]

No new shares is good news. But I was also glad to see the information contained in the paragraph I quoted below. One question I would like the answer to is this, "Will the company be looking to add additional clinical sites in order to speed up the CX trial?" And if the answer is "No" then I want to know, "Why not?"

That CX trial is scheduled to last through the end of 2017. It is interesting that this schedule means that the GALTW warrants expire 6 months before the end of the company's primary Phase 2 trial. Coincidence or...?

Dr. Traber continued, "Last week, Galectin began an expansion of its initiative to communicate with investors and other interested parties with the commencement of a blog on our website, entitled CEO Perspectives. Our goal is to provide a forum through which we may help investors and members of the public understand our programs and answer questions that we routinely receive. I am enthusiastic about this opportunity to discuss the exciting activities not only at Galectin in NASH, but also in the study of other fibrotic and immunogenic diseases where our compounds might be tested. We will be posting to the blog on a regular basis."
- From the PR